Elvitegravir with tipranavir/ritonavir or darunavir/ritonavir

HIV Treat Bull - 2009 Jan-Feb;10(1/2): 29

Two studies are described evaluating potential pharmacokinetic interactions among elvitegravir and ritonavir-boosted tipranavir or darunavir.

In the tipranavir study healthy volunteers received elvitegravir/ritonavir (200/100 mg once daily) alone, or tipranavir/ritonavir (500/200 mg twice daily) alone, or elvitegravir (200 mg once daily) in combination with tipranavir/ritonavir (500/200 mg twice daily). For the darunavir study subjects received elvitegravir/ritonavir (125/100 mg once daily) alone, or darunavir /ritonavir (600/100 mg twice daily) alone, or elvitegravir (125 mg once daily) in combination with darunavir /ritonavir (600/100 mg twice daily). Steady state pharmacokinetics for elvitegravir, tipranavir, darunavir and ritonavir were determined. No subjects discontinued for adverse events during treatment with elvitegravir/ritonavir alone. On coadministration, AUC and Cmax of elvitegravir/tipranavir and elvitegravir/darunavir were within prespecified no-effect boundaries versus treatment alone; trough concentrations were also not substantially altered. The authors concluded that elvitegravir can be added to tipranavir/ritonavir or darunavir/ritonavir regimens without dose adjustment.

Ref: Mathias AA et al. Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir. J Acquir Immune Defic Syndr. 2008 Oct 1;49(2):156-62.

2009-02-10
IB2009-01-29

©2009. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.